- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07478237
The Preventive Risk Outreach And Cascade Testing (PROACT)
The Preventive Risk Outreach and Cascade Testing (PROACT)
The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The overarching goal of this study is to facilitate cascade genetic testing to reduce the burden of cancer in families with hereditary cancer syndromes (HCS). We will evaluate different versions of a point-of-care cascade genetic testing referral service for probands with recently detected pathogenic or likely pathogenic genetic variants.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sonia Rios-Ventura
- Phone Number: 6507258762
- Email: proactprogram@stanford.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria - Probands
- Age ≥ 18 years old.
- Known to carry a pathogenic or likely pathogenic variant in a gene included in the 2024 current Color Health Cancer Panel Test.
- Have at least one (1) first- or second-degree relative who is living in the United States and has not yet had germline genetic testing.
Exclusion Criteria - Probands
1. Unable to read and write English or Spanish.
Inclusion Criteria - Relatives
- Age ≥ 18 years old.
- Resides in the United States.
Exclusion Criteria - Relatives
- Completed genetic testing by a clinician within the last 5 years that included the pathogenic or likely pathogenic variant.
- Not a first- or second-degree relative of the proband.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PROACT Platform - Minimally Facilitated Testing
The Minimally Facilitated testing arm is a simplified version of the PROACT-AI platform, that provides participants with access to low-cost testing only, in addition to standard of care. |
This group will receive access to low-cost genetic testing via an email link and an access code. |
|
Experimental: PROACT Platform - AI
The AI-powered arm will provide participants access to low-cost testing via an AI-powered platform as well as provide additional features including genetic education, motivational interviewing, family communication, and complete follow-up surveys. |
This group will receive access to low-cost genetic testing via an AI-powered platform that will also provide genetic education, motivational interviewing, and family communication |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm
Time Frame: 6 months
|
Proportion of all eligible first- and second-degree relatives who undergo genetic testing through Color Health in each study arm |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm
Time Frame: 6 months
|
Proportion of eligible first-degree relatives who undergo genetic testing through Color Health in each study arm |
6 months
|
|
Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm
Time Frame: 6 months
|
Proportion of index patients for whom at least one eligible relative undergoes genetic testing through Color Health in each study arm |
6 months
|
|
Proportion of eligible relatives invited by the patient in each study arm
Time Frame: 180 days
|
Proportion of eligible relatives invited by the patient in each study arm |
180 days
|
|
Proportion of eligible relatives who join the PROACT program in each study arm
Time Frame: 28 days
|
Proportion of eligible relatives who join the PROACT program in each study arm |
28 days
|
|
Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only]
Time Frame: 180 days
|
Proportion of relatives who completed the genetic risk education modules as measured by platform paradata [PROACT platform-AI Arm Only] |
180 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess Relatives' appraisal of their decision making about genetic testing
Time Frame: 180 days +/- 90 days
|
Assess Relatives' appraisal of their decision making about genetic testing, as measured by the Decision Quality Scale. The minimum value for the Decision Quality Scale is 7, and the maximum value is 35. A higher score on this scale indicates a better outcome, i.e. a higher score reflects a more positive appraisal of PROACT by relatives regarding their decision-making about genetic testing. |
180 days +/- 90 days
|
|
Relatives' confidence in their understanding of hereditary cancer risk
Time Frame: 180 days +/- 90 days
|
To compare enrolled relatives' confidence in their understanding of hereditary cancer risk, using interviews. |
180 days +/- 90 days
|
|
Compare the proportion of eligible relatives who requested genetic testing in each study arm
Time Frame: 6 months
|
Using survey responses, compare the proportion of eligible relatives who requested genetic testing within 6 months of enrollment in each study arm, as measured by survey responses. |
6 months
|
|
Assess Index patients' appraisal of communication with their relatives
Time Frame: 180 days +/- 90 days
|
Assess Index patients' appraisal of communication with their relatives, as measured by a modified Patient Assessment of Family Communication Scale. The minimum value of the scale is 10, and the maximum value is 50. A higher score, controlling for baseline, indicates a greater improvement in the patient's assessment of their communication with relatives. |
180 days +/- 90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Allison Kurian, MD, Stanford University
- Principal Investigator: Jennifer Lee Caswell-Jin, MD, Stanford University
- Principal Investigator: Steven Katz, MD, University of Michigan
- Principal Investigator: Lawrence An, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 82980
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.